Hunan Warrant Showcases New Manufacturing Capabilities and Strengthens Global Partnerships at CPHI Shanghai 2026

By HWC Pharma | Updated: 2026-06-22 10:47:57

Hunan Warrant Chiral Pharmaceutical Co., Ltd., a leading provider of pharmaceutical APIs, intermediates and excipients, concluded a highly successful participation at the 2026 CPHI China, held from June 16-18 in Shanghai.  

It was good to catch up with our long-term partners face-to-face — we reviewed ongoing projects, discussed upcoming demand, and aligned on quality and delivery expectations for the second half of the year. We also engaged with a significant number of new prospects from various countries across Europe, the Americas, and Southeast Asia. These initial conversations have opened up promising opportunities for new product development and market entry. 

We also took the opportunity to introduce our newly built production plant, Hunan Warrant Zhigen Pharmaceutical Co., Ltd., which officially went into operation in June this year. The new factory is also located in the National Industrial Park in Wangcheng District of Changsha, covering an area of about 160,000 m², mainly targeting international markets such as Europe and America. It plans to scale up the production of products such as Clopidogrel Bisulfate, Ticagrelor and its intermediates, and Sugammadex Sodium, etc..